NASDAQ:ELVN Enliven Therapeutics (ELVN) Stock Price, News & Analysis → RE: Your account status (From MarketBeat) (Ad) Free ELVN Stock Alerts $23.22 -0.72 (-3.01%) (As of 05/28/2024 ET) Add Compare Share Share Today's Range$22.14▼$24.3450-Day Range$16.78▼$24.7052-Week Range$9.80▼$26.00Volume221,804 shsAverage Volume259,939 shsMarket Capitalization$1.09 billionP/E RatioN/ADividend YieldN/APrice Target$34.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Enliven Therapeutics alerts: Email Address Enliven Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside46.4% Upside$34.00 Price TargetShort InterestBearish19.75% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.99Based on 5 Articles This WeekInsider TradingSelling Shares$28.56 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.26) to ($2.74) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.77 out of 5 starsMedical Sector674th out of 931 stocksPharmaceutical Preparations Industry317th out of 433 stocks 3.5 Analyst's Opinion Consensus RatingEnliven Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageEnliven Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Enliven Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted19.75% of the float of Enliven Therapeutics has been sold short.Short Interest Ratio / Days to CoverEnliven Therapeutics has a short interest ratio ("days to cover") of 16.1, which indicates bearish sentiment.Change versus previous monthShort interest in Enliven Therapeutics has recently increased by 12.05%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEnliven Therapeutics does not currently pay a dividend.Dividend GrowthEnliven Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ELVN. Previous Next 2.8 News and Social Media Coverage News SentimentEnliven Therapeutics has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Enliven Therapeutics this week, compared to 2 articles on an average week.Search Interest2 people have searched for ELVN on MarketBeat in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enliven Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $28,555,948.00 in company stock.Percentage Held by Insiders29.20% of the stock of Enliven Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.08% of the stock of Enliven Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Enliven Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Enliven Therapeutics are expected to decrease in the coming year, from ($2.26) to ($2.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enliven Therapeutics is -12.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enliven Therapeutics is -12.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnliven Therapeutics has a P/B Ratio of 3.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Enliven Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressNew trading system called MSFT, NVDA & MSFTLook 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here! About Enliven Therapeutics Stock (NASDAQ:ELVN)Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Read More ELVN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ELVN Stock News HeadlinesMay 21, 2024 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Director Rishi Gupta Sells 1,033,300 SharesMay 17, 2024 | insidertrades.comAnish Patel Sells 1,107 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockMay 9, 2024 | insidertrades.comInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells 4,875 Shares of StockMay 8, 2024 | insidertrades.comBenjamin Hohl Sells 1,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockMay 3, 2024 | insidertrades.comBenjamin Hohl Sells 3,250 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockMay 2, 2024 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $55,152.50 in StockApril 30, 2024 | insidertrades.comSamuel Kintz Sells 12,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockMay 22, 2024 | americanbankingnews.comEnliven Therapeutics (NASDAQ:ELVN) Shares Down 5% After Insider SellingMay 21, 2024 | americanbankingnews.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Director Rishi Gupta Sells 1,033,300 Shares of StockMay 18, 2024 | americanbankingnews.comEquities Analysts Issue Forecasts for Enliven Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:ELVN)May 15, 2024 | finanznachrichten.deEnliven Therapeutics, Inc.: Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business UpdateMay 15, 2024 | investorplace.comELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q1 2024May 14, 2024 | globenewswire.comEnliven Therapeutics Reports First Quarter Financial Results and Provides a Business UpdateApril 28, 2024 | nasdaq.comCommit To Purchase Enliven Therapeutics At $10, Earn 11.2% Annualized Using OptionsApril 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for Apellis Pharmaceuticals Amid Positive Outlook and Growth PotentialApril 26, 2024 | markets.businessinsider.comBuy Rating Affirmed: Enliven Therapeutics’ ELVN-001 Shows Market Potential and Efficacy in Resistant PatientsApril 19, 2024 | finance.yahoo.comMasterCraft Boat, SentinelOne, and More Stocks See Action From Activist InvestorsApril 18, 2024 | msn.comEnliven Therapeutics files to sell 6.43M shares for holdersApril 17, 2024 | msn.comEnliven Therapeutics (ELVN) Price Target Increased by 10.75% to 35.02April 16, 2024 | investing.comEnliven Therapeutics CMO sells $501k in company stockApril 12, 2024 | investing.comEnliven reports promising Phase 1 data for leukemia drugApril 11, 2024 | markets.businessinsider.comStrong Buy Rating for Enliven Therapeutics’ ELVN-001 Following Outstanding Phase 1 Results and Market PotentialApril 11, 2024 | finance.yahoo.comEnliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead ProgramApril 11, 2024 | msn.comEnliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On ThursdayApril 11, 2024 | marketwatch.comEnliven Therapeutics Shares Hit 52-Week High After Positive Proof of Concept Data for Blood Cancer DrugSee More Headlines Receive ELVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enliven Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today5/28/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ELVN CUSIPN/A CIK1672619 Webimaratx.com Phone617-927-9989FaxN/AEmployees46Year FoundedN/APrice Target and Rating Average Stock Price Target$34.00 High Stock Price Target$34.00 Low Stock Price Target$34.00 Potential Upside/Downside+47.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-71,580,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-28.83% Return on Assets-27.05% Debt Debt-to-Equity RatioN/A Current Ratio13.47 Quick Ratio13.47 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.97 per share Price / Book3.87Miscellaneous Outstanding Shares47,040,000Free Float33,302,000Market Cap$1.09 billion OptionableOptionable Beta1.05 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Samuel S. Kintz M.B.A. (Age 38)Co-Founder, CEO, Secretary & Director Comp: $597kDr. Helen Louise Collins M.D. (Age 61)Chief Medical Officer Comp: $558kDr. Joseph P. Lyssikatos Ph.D. (Age 59)Co-Founder, Chief Scientific Officer & Directors Dr. Galya D. Blachman Esq. (Age 47)Ph.D., Chief Legal Officer & Head of Business Development Key CompetitorsAvadel PharmaceuticalsNASDAQ:AVDLEditas MedicineNASDAQ:EDITFulcrum TherapeuticsNASDAQ:FULCDelcath SystemsNASDAQ:DCTHbluebird bioNASDAQ:BLUEView All CompetitorsInsiders & InstitutionsJanus Henderson Group PLCBought 305,397 shares on 5/16/2024Ownership: 1.519%Rishi GuptaSold 1,033,300 sharesTotal: $22.88 M ($22.14/share)Blackstone Inc.Bought 25,191 shares on 5/16/2024Ownership: 0.054%California State Teachers Retirement SystemSold 1,189 shares on 5/16/2024Ownership: 0.041%Baker BROS. Advisors LPBought 114,833 shares on 5/15/2024Ownership: 0.244%View All Insider TransactionsView All Institutional Transactions ELVN Stock Analysis - Frequently Asked Questions Should I buy or sell Enliven Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Enliven Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ELVN shares. View ELVN analyst ratings or view top-rated stocks. What is Enliven Therapeutics' stock price target for 2024? 1 analysts have issued 1-year price objectives for Enliven Therapeutics' shares. Their ELVN share price targets range from $34.00 to $34.00. On average, they predict the company's stock price to reach $34.00 in the next year. This suggests a possible upside of 46.4% from the stock's current price. View analysts price targets for ELVN or view top-rated stocks among Wall Street analysts. How have ELVN shares performed in 2024? Enliven Therapeutics' stock was trading at $13.84 at the beginning of 2024. Since then, ELVN shares have increased by 67.8% and is now trading at $23.22. View the best growth stocks for 2024 here. Are investors shorting Enliven Therapeutics? Enliven Therapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 5,300,000 shares, an increase of 12.1% from the April 30th total of 4,730,000 shares. Based on an average trading volume of 329,500 shares, the days-to-cover ratio is presently 16.1 days. Approximately 19.8% of the shares of the company are short sold. View Enliven Therapeutics' Short Interest. When is Enliven Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our ELVN earnings forecast. How were Enliven Therapeutics' earnings last quarter? Enliven Therapeutics, Inc. (NASDAQ:ELVN) announced its earnings results on Thursday, March, 14th. The company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.56) by $0.09. What ETFs hold Enliven Therapeutics' stock? ETFs with the largest weight of Enliven Therapeutics (NASDAQ:ELVN) stock in their portfolio include Loncar China Biopharma ETF (CHNA).Range Cancer Therapeutics ETF (CNCR). Who are Enliven Therapeutics' major shareholders? Enliven Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.52%), Janus Henderson Group PLC (1.52%), Baker BROS. Advisors LP (0.24%), Blackstone Inc. (0.05%), California State Teachers Retirement System (0.04%) and EntryPoint Capital LLC (0.02%). Insiders that own company stock include 5Am Partners Vi, Llc, Anish Patel, Benjamin Hohl, Joseph P Lyssikatos, Rahul D Ballal, Richard A Heyman, Rishi Gupta and Samuel Kintz. View institutional ownership trends. How do I buy shares of Enliven Therapeutics? Shares of ELVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ELVN) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersDigitizing the $11T commodities sector with one tiny stockResource Stock DigestNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemWeiss RatingsHe Is Giving Away BitcoinCrypto Swap ProfitsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersElon’s New Device is About to Shock the WorldInvestorPlaceMissed NVDA? Buy this AI stock NOWChaikin AnalyticsThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
